Abstract
We have not added the abstract for this paper yet. The publisher's page has the full record.
The influence of baseline Alzheimer's disease severity on cognitive decline and CSF biomarkers in the NILVAD trial
Frontiers in Neurology · pp. 149 Published January 1, 2020
More on these topics
Browse all publications →-
2026 · Alzheimers Dement.
Evaluating digital cognitive tests for clinical use in Alzheimer's disease: A novel framework and scoping review
-
2026 · Stat Med.
Time-Scale Target Parameters and Two-Step Estimation in Longitudinal Trials for Progressive Diseases
-
2026 · Nat Med
Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease
-
2026 · Alzheimers Dement
Biomarkers in patients with clinical signs of mild cognitive impairment or mild Alzheimer's disease but without amyloid deposits on positron emission tomography: Results from Bio-Hermes Study participants